Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021

Rhea-AI Summary

Clearside Biomedical (NASDAQ:CLSD) will report its first quarter 2021 financial results on May 17, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing insights into financial performance and corporate updates. Clearside, dedicated to treatments for serious back of the eye diseases, utilizes its proprietary SCS Microinjector to deliver medications effectively. The live and archived webcasts will be accessible on the Clearside website, with contact information for investor inquiries provided.

Positive

• Scheduled earnings report indicates transparency and regular communication with investors.
• Proprietary SCS Microinjector represents a competitive edge in the biopharmaceutical sector.

Negative

• None.

ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its first quarter 2021 financial results will be reported on Monday, May 17, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 1488886. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector^® targets the suprachoroidal space (SCS^®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical report its first quarter 2021 financial results?

Clearside Biomedical will report its first quarter 2021 financial results on May 17, 2021.

What time is the conference call for Clearside's financial results?

The conference call will be held at 4:30 p.m. Eastern Time on May 17, 2021.

How can investors access the webcast for Clearside Biomedical's earnings report?

Investors can access the live and archived webcast on the Clearside website under the Investors section.

What is the significance of the SCS Microinjector developed by Clearside?

The SCS Microinjector allows targeted delivery of medications for treating serious back of the eye diseases.